SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (9507)1/30/2003 6:52:47 AM
From: dalroi  Read Replies (1) | Respond to of 9719
 
antegren results comming which are good for crohn ?

Stefaan



To: Icebrg who wrote (9507)1/30/2003 12:30:54 PM
From: Vector1  Read Replies (3) | Respond to of 9719
 
Iceberg,
Reasons for MLNM sale
Spending at an alarming rate
Obesity program a failure
$560m of debt coming due
IMO Velcade has less than 50% chance of approval on phase II trial. Looks desperate to me. If at end of 60 day period FDA accepts submission I may reconsider.
Integrin is a good product but modest growth ahead.
V1


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News